Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$34 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
-0.6
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
10,139,900
CFO
$-132.26 Mln
EBITDA
$-103.24 Mln
Net Profit
$-191.15 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
| 11.8 | -3.0 | 32.4 | 52.4 | -28.3 | -49.7 | -34.1 |
|
BSE Sensex*
| 4.4 | -0.4 | 8.3 | 5.6 | 16.7 | 18.7 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
| -3.9 | -60.3 | -51.5 | -86.7 | 194.5 | -11.7 | -24.6 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
3.3 | 34.2 | 0.0 | -11.6 | -- | -19.7 | -- | 0.6 |
| 3.5 | 664.6 | 6.4 | -76.6 | -1,194.0 | -82.3 | -- | 8.4 | |
| 4.7 | 324.2 | 320.2 | 8.7 | 10.7 | 2 | 29.3 | 0.6 | |
| 6.2 | 2,177.7 | 9,601.6 | -42.6 | 16.3 | -- | -- | 18.8 | |
| 1.3 | 287.3 | 267.5 | -594.7 | -194.1 | -120.8 | -- | 0.7 | |
| 1.9 | 736.2 | 124.6 | 49.4 | -37.5 | 4.5 | 13.6 | 0.7 | |
| 3.0 | 10.1 | 54.5 | -4.8 | -9.7 | -70.9 | -- | 2.5 | |
| 30.2 | 57.3 | 0.0 | -14.2 | -- | -114.9 | -- | 10.0 | |
| 30.2 | 57.3 | 0.0 | -20.9 | -- | -183.1 | -- | 10.0 | |
| 1.3 | 329.3 | 927.6 | -107.0 | -11.3 | -9.3 | -- | 0.4 | |
| 2.5 | 113.1 | 88.7 | -3.7 | 7.3 | -- | -- | 20.1 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid... hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. Read more
CEO & Director
Mr. Prashant Kohli
CEO & Director
Mr. Prashant Kohli
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Acasti Pharma Inc Class A - ADR stood at $ 68 Mln as on 30-Sep-24
The share price of Acasti Pharma Inc Class A - ADR is $3.28 (NASDAQ) as of 21-Nov-2024 09:30 EDT. Acasti Pharma Inc Class A - ADR has given a return of -28.29% in the last 3 years.
Acasti Pharma Inc Class A - ADR has a market capitalisation of $ 34 Mln as on 22-Nov-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Acasti Pharma Inc Class A - ADR is 0.59 times as on 22-Nov-2024, a 93% discount to its peers’ median range of 8.66 times.
Since, TTM earnings of Acasti Pharma Inc Class A - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Acasti Pharma Inc Class A - ADR and enter the required number of quantities and click on buy to purchase the shares of Acasti Pharma Inc Class A - ADR.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
The CEO & director of Mr. Prashant Kohli. is Acasti Pharma Inc Class A - ADR, and CFO & Sr. VP is Mr. Prashant Kohli.
There is no promoter pledging in Acasti Pharma Inc Class A - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
279
|
|
|
75
|
|
|
69
|
|
|
49
|
|
|
45
|
|
|
26
|
|
|
7
|
|
|
1
|
|
|
1
|
| Acasti Pharma Inc. Class A - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-19.69
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Acasti Pharma Inc Class A - ADR was $0 Mln.
$-0.09
(
